Elevating Commercial Capability for Emerging BioPharma
03
We built ElevEx BioGroup to close that gap; from the inside, not from a slide deck. We work alongside founder-led, PE and VC-backed companies where the margin for error is smallest and the timeline never moves in your favor.
02
We don't arrive with a predetermined answer. We arrive with the knowledge, experience, tools, and execution to find the right one; and the judgment to know when what's already in the room is better than anything we brought with us.
01
When commercial readiness lags the science, launches stumble, payers don't move, and patients wait longer than they should. Not because the science isn't there. Because the infrastructure underneath it wasn't built in time.
Science is moving faster than commercial readiness. That gap doesn't close on its own.
WHERE WE SHOW UP
Every engagement starts with a situation
We meet you where the pressure is.
PRE-MARKET
Pre-launch readiness
The infrastructure gap reveals itself at the worst possible time.
LAUNCH & GROWTH
Commercial launch
The plan is ready. The infrastructure to execute it isn't.
PERFORMANCE & CHANGE
Commercial transformation
Built for a market that was just getting started.
THREAT & NEW ENTRY
Competitive entry
Defense without a plan is just a slower loss.
Indication expansion
The evidence exists. The commercial architecture is conflicted.
Scaling
What got you to launch won't get you through growth.
Performance plateau
Growth has stalled. The reasons haven't been diagnosed.
Coverage loss / crisis
Coverage disappears. Everything downstream stops with it.
WHAT WE DO
Commercial capabilities built to remove obstacles.
We work between your team and the ecosystem around it: connecting evidence to access, access to execution.
MARKET ACCESS
Without access, every other action fails to reach its potential.
Built to close the gap between what the FDA approved and what the payer will cover.
-
Prior auth pull-through strategy
-
Step therapy navigation and prescriber support
-
SP network optimization
-
PSP utilization at point of prescribing
-
Formulary tier positioning and contracting
COMMERCIAL OPERATIONS
The infrastructure that turns strategy into revenue.
Built to deliver: stood up at the speed your stage demands.
-
Field force deployment and redesign
-
Field force effectiveness (FFE)
-
CSO strategy, design, and optimization
-
Turning performance data into revenue decisions
-
Converting formulary wins into scripts
CLINICAL TO COMMERCIAL
Clinical strategy is commercial strategy.
Built for the market you're entering, not the one that looked good in the forecast.
-
Indication-specific value proposition and payer narrative
-
Evidence gap analysis for the new population
-
Label expansion and prescriber education strategy
-
Payer sequencing for new indication launch
-
Lifecycle positioning
HOW WE WORK
How we show up
No lengthy onboarding. No methodology decks. Just experienced people getting oriented fast and focusing on what matters.
WE START BY LISTENING
We start with your situation, not a rote checklist.
We diagnose before we prescribe, each and every time.
WE WORK ALONGSIDE YOU
We work as part of your team, not above it.
Working alongside whatever tools and partners are already in the room, forging the next steps.
WE MOVE AT YOUR SPEED
We move at the speed your stage demands.
Oriented fast, decisive with incomplete information, no momentum lost.
WE STAY UNTIL IT WORKS
Seeing the work through without pause.
We execute relentlessly until the defined objectives are achieved.
When The Phone Rings
These are the conversations that start it.
No two engagements begin the same way.
But the pressure behind them always sounds familiar.
01
We just closed Series C and our board wants a launch plan by Q3.
We don't have a commercial team yet.
02
Our VP of Commercial just left. Launch is 90 days out.
We can't pause.
03
We've been told our payer strategy is solid but we're getting pushback in every meeting. Something isn't working.
04
We just acquired a company and the integration is a mess. Two CRMs, two field forces, nobody trusts the numbers.
05
We're in a category that's never existed.
There is no playbook for what we're trying to do.
06
We cut 40% of the commercial team last quarter. The launch timeline didn't move.
The headcount is gone. The work isn't.
THIS IS HOW WE THINK
We have opinions. Let's discuss.
Perspectives from practitioners who have been inside the challenges, not observing from the outside.
01
HEOR & Market Access
The problem isn't a lack of evidence ... it's a lack of direction on where effort should be targeted.
Break the Silos: How Early Integration of HEOR and Market Access Drives Commercial Success
Most biopharma companies engage HEOR and Market Access too late, then scramble after Phase 3 with evidence that doesn't resonate with payers.
This paper makes the case for designing evidence backward from payer needs, starting years before launch.
Coming Soon
Designing Patient-First Support Models
Coming Soon